Bristol-Myers Squibb- WuXi AppTec Analytical and Stability Center Unveiling Ceremony Successfully Held
Jun 03, 2011
On June 1, 2011, WuXi AppTec successfully held the Bristol-Myers Squibb- WuXi AppTec analytical and stability center unveiling ceremony.
Dr. Stephen Scypinski, Vice President of Analytical & Bioanalytical Development of Bristol-Myers Squibb, Dr. Pankaj Shah, Executive Director of Analytical & Bioanalytical Development of Bristol-Myers Squibb, Dr. Cezary Statuch, Vice President and Head of China R&D and Global Medical Japan and India of Bristol-Myers Squibb, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec, Dr. Suhan Tang, Chief Manufacturing Officer of WuXi AppTec, Dr. Eugene Gong, Vice President of Analytical R&D of WuXi AppTec and other management team members from BMS and WuXi AppTec attended the ceremony and together celebrated the unveiling.
The dedicated center is fully cGMP-compliant and covers an area of 25,000-square-foot, to provide stability testing, sample management, analytical testing, pharmaceutical science, quality assurance, metrology, and other services, including stability data reporting in support of all global dossier submissions by Bristol-Myers Squibb with highly-skilled staff.
In the ceremony, on behalf of BMS, Dr. Scypinski awarded Dr. Ge Li, Dr. Eugene Gong, Yifeng Yi, Jennifer Lin, Fang Liu, and Yong Yin with Bristol Mayers Squibb Strategic Alliance Award in recognition of their outstanding contribution to the collaboration.
“It is indeed an honor and pleasure standing here before you today. Today marks not only a milestone but commemorates a reinvention journey that began for BMS several years ago.” commented Dr. Stephen Scypinski, Vice President of Analytical & Bioanalytical Development of Bristol-Myers Squibb. “Reinvention called upon ‘three Pillars’ –continuous improvement, innovation and selective integration. The establishment of the Bristol-Myers Squibb- WuXi AppTec analytical and stability center is a successful example of the implementation of the above three elements.”
“Today symbolizes the milestone for new life, and for new collaboration.” commented Dr. Ge Li. “The industry is evolving and transforming. WuXi, as a service company, is determined to serve our partners and the industry better. But most importantly, the innovative companies, like BMS and the service companies, like WuXi need to work together to find a better ways to discover and develop drugs more cost-effectively and more efficiently for patients.”